GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (STU:69C) » Definitions » Cyclically Adjusted PB Ratio

Cara Therapeutics (STU:69C) Cyclically Adjusted PB Ratio : 0.22 (As of May. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cara Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-19), Cara Therapeutics's current share price is €0.6805. Cara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.10. Cara Therapeutics's Cyclically Adjusted PB Ratio for today is 0.22.

The historical rank and industry rank for Cara Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:69C' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.16   Med: 1.23   Max: 5.49
Current: 0.21

During the past years, Cara Therapeutics's highest Cyclically Adjusted PB Ratio was 5.49. The lowest was 0.16. And the median was 1.23.

STU:69C's Cyclically Adjusted PB Ratio is ranked better than
81.3% of 647 companies
in the Biotechnology industry
Industry Median: 1.75 vs STU:69C: 0.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cara Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €0.502. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.10 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cara Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cara Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Cyclically Adjusted PB Ratio Chart

Cara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.15 0.21

Cara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 0.82 0.48 0.21 0.25

Competitive Comparison of Cara Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Cyclically Adjusted PB Ratio falls into.



Cara Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cara Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.6805/3.1
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cara Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.502/131.7762*131.7762
=0.502

Current CPI (Mar. 2024) = 131.7762.

Cara Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.002 100.560 2.623
201409 1.885 100.428 2.473
201412 1.837 99.070 2.443
201503 1.920 99.621 2.540
201506 1.657 100.684 2.169
201509 3.726 100.392 4.891
201512 3.538 99.792 4.672
201603 3.124 100.470 4.097
201606 2.694 101.688 3.491
201609 2.345 101.861 3.034
201612 1.762 101.863 2.279
201703 0.844 102.862 1.081
201706 2.985 103.349 3.806
201709 2.549 104.136 3.226
201712 2.245 104.011 2.844
201803 1.788 105.290 2.238
201806 1.837 106.317 2.277
201809 3.253 106.507 4.025
201812 2.970 105.998 3.692
201903 2.561 107.251 3.147
201906 2.201 108.070 2.684
201909 4.122 108.329 5.014
201912 3.597 108.420 4.372
202003 3.108 108.902 3.761
202006 2.670 108.767 3.235
202009 2.315 109.815 2.778
202012 4.104 109.897 4.921
202103 3.870 111.754 4.563
202106 3.372 114.631 3.876
202109 3.510 115.734 3.997
202112 3.765 117.630 4.218
202203 3.458 121.301 3.757
202206 3.600 125.017 3.795
202209 3.474 125.227 3.656
202212 2.786 125.222 2.932
202303 2.364 127.348 2.446
202306 1.860 128.729 1.904
202309 1.473 129.860 1.495
202312 0.961 129.419 0.979
202403 0.502 131.776 0.502

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cara Therapeutics  (STU:69C) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cara Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics (STU:69C) Business Description

Traded in Other Exchanges
Address
107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Cara Therapeutics (STU:69C) Headlines

No Headlines